Search

Your search keyword '"Le, Anh T."' showing total 507 results

Search Constraints

Start Over You searched for: Author "Le, Anh T." Remove constraint Author: "Le, Anh T."
507 results on '"Le, Anh T."'

Search Results

1. Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

2. Direct observation of the Yb(4f13 6s2)F states and accurate determination of the YbF ionization energy

6. Observation and laser spectroscopy of ytterbium monomethoxide, YbOCH$_3$

7. The 1.66 $\mu$m Spectrum of the Ethynyl Radical, CCH

8. Branching ratios, radiative lifetimes and transition dipole moments for YbOH

12. Vietnamese Graduate International Student Repatriates: Reverse Adjustment

13. Analysis of the $\tilde{A}-\tilde{X}$ bands of the Ethynyl Radical near 1.48$\mu$m and Re-evaluation of $\tilde{X}$ State Energies

15. Institutional Autonomy of Vietnamese Public Universities: An Agency Theory Perspective.

16. International Female Graduate Students' Experience at a Midwestern University: Sense of Belonging and Identity Development

17. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

18. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

19. High resolution electronic spectroscopy of uranium mononitride, UN.

20. The near-infrared spectrum of ethynyl radical

26. Supplementary Figures S1-9 from MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

30. The Multi-path Utility Maximization and Multi-path TCP Design

31. Educational Attainment in Australia: A Cohort Analysis. Research Report.

32. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

38. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

39. ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

41. Supplementary Figure Legends from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

42. Supplementary Figures 1 - 5 from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

44. Data from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

46. Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

47. Supplementary Figures 1-5 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

48. Supplementary Figure 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

49. Supplementary Figures 1-5, Tables 1-2 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources